EUCTR2009-015614-21-IT进行中（未招募）不适用
Stereotactic accelerated radiotherapy concurrent with Temozolomide chemotherapy in newly diagnosed glioblastoma - ND
ISTITUTO NEUROLOGICO CARLO BESTA0 个研究点开始时间: 2009年12月4日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •* Newly diagnosed supra-tentorial glioblastoma, surgically resected * Radiologically proved surgical resection of the tumor mass * Age between 18 and 65 years * Karnofski Performance Status ≥ 70 * Bone marrow, liver and kidney standard functionality * No concomitant infections * Life expectancy > 12 weeks * Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •* Brain neoplasia for which histological diagnosis is not available * Newly diagnosed glioblastoma, obtained by biopsy * Glioblastoma with dissemination subependimal * Tissue histology not available * Age > 65 and <18-aa * Karnofski Performance Status <70 * Severely impaired bone marrow function, liver, kidney * Co-infected * Pregnancy * Pregresso chemotherapy and / or radiotherapy
研究者
相似试验
已完成
2 期
Addition of stereotactic radiotherapy to the standard FOLFIRINOX treatment in locally advanced pancreatic cancer patients to determine efficacy and feasability (LAPC-1)locally advanced pancreatic carcinoma1001567410017991Pancreatic cancerNL-OMON44466Stichting Leveronderzoek51
Unknown
不适用
Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.locally advanced pancreatic cancerpancreatic neoplasmFOLFIRINOXstereotactic radiotherapyNL-OMON27030Foundation for Liver and Gastrointestinal Research51
进行中（未招募）
2 期
SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.Oligometastatic or oligoprogressive ovarian, fallopian tube or primary peritoneal carcinomaCancerISRCTN13282459Institute of Cancer Research Clinical Trial & Statistics Unit42
招募中
1 期
Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate cancer. Phase II Spanish study, prospective, multicenter. (OLIGORESIST)Oligometastatic patients with castration-resistant prostate cancerCTIS2023-505024-62-01Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)51
已完成
2 期
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trialcancer spread to other parts of the bodymetastatic cancer10027476NL-OMON37922Vrije Universiteit Medisch Centrum20